{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreia5kjutpqjev43p24uo77cwhw3bpkezztmyas27c7vumwrq3a6kmq",
    "uri": "at://did:plc:xc32dedgv3ceunwz2nrseso4/app.bsky.feed.post/3mltbc5yay7c2"
  },
  "path": "/x/538dd9aa8cf35991?ref=rss",
  "publishedAt": "2026-05-14T16:36:52.000Z",
  "site": "https://upstract.com",
  "textContent": "Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease CELIA did not meet its primary endpoint assessing dose response; based on the strength of the biomarker and efficacy…",
  "title": "Topline Results from Phase 2 CELIA Study of Diranersen (BIIB080): First Study to Show Reduction in Tau Pathology and Cognitive Benefit in Patients with Early Alzheimer’s Disease"
}